Changes Over Time in Risk of Initial Virological Failure of Combination Antiretroviral Therapy

This publication has 23 references indexed in Scilit:

• An audit of antiretroviral treatment use in HIV-infected patients in a London clinic: the limitations of observational databases when auditing antiretroviral treatment use
  HIV Medicine, 2003
• Hepatotoxicity in HIV-1-infected patients receiving nevirapine-containing antiretroviral therapy
  AIDS, 2001
• Overview of the effectiveness of triple combination therapy in antiretroviral-naive HIV-1 infected adults
  AIDS, 2001
• Determinants of sustainable CD4 lymphocyte count increases in response to antiretroviral therapy
  AIDS, 1999
• Discontinuation of Primary Prophylaxis againstPneumocystis cariniiPneumonia in HIV-1–Infected Adults Treated with Combination Antiretroviral Therapy
  New England Journal of Medicine, 1999
• Virological response to protease inhibitor therapy in an HIV clinic cohort
  AIDS, 1999
• Risk of new AIDS diseases in people on triple therapy
  The Lancet, 1999
• Factors Influencing the Emergence of Resistance to Indinavir: Role of Virologic, Immunologic, and Pharmacologic Variables
  The Journal of Infectious Diseases, 1998
• The duration of viral suppression during protease inhibitor therapy for HIV-1 infection is predicted by plasma HIV-1 RNA at the nadir
  AIDS, 1998
• A Controlled Trial of Two Nucleoside Analogues plus Indinavir in Persons with Human Immunodeficiency Virus Infection and CD4 Cell Counts of 200 per Cubic Millimeter or Less
  New England Journal of Medicine, 1997